Nanostructured Lipid Carrier-Based Nanoformulations for Atopic Dermatitis: A Comprehensive Review

Pratik Singh

doi:10.52228/JRUB.2025-38-2-11

Journal of Ravishankar University

Pt. Ravishankar Shukla University, Raipur, Chhattisgarh

PART-B

(SCIENCE)

ISSN: 0970-5910

Abstract View

Submit Article

Nanostructured Lipid Carrier-Based Nanoformulations for Atopic Dermatitis: A Comprehensive Review

Author(s): Pratik Singh

Email(s): pratikkshatri1234@gmail.com

Address: Sun Pharma R&D Vadodara Gujarat, India.
Rungta College of pharmaceutical science and research, Bhilai.
*Corresponding Author: pratikkshatri1234@gmail.com

Published In: Volume - 38, Issue - 2, Year - 2025

DOI: 10.52228/JRUB.2025-38-2-11

View HTML

View PDF

ABSTRACT:
Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by barrier dysfunction, immune dysregulation, and pruritus. Conventional therapies often show limited efficacy due to poor skin penetration, side effects, and low adherence. Nanostructured lipid carriers (NLCs) offer a promising topical drug delivery platform to enhance skin targeting, controlled release, and patient compliance. This review highlights NLC design, formulation strategies, dermal penetration mechanisms, and immunomodulatory potential, with preclinical and emerging clinical evidence for corticosteroid-, immunosuppressant-, and phytochemical-loaded systems. Safety, regulatory considerations, and translational challenges are discussed, emphasizing the need for stimuli-responsive and personalized NLC approaches for effective AD management.

Keywords:

Cite this article:
Singh (2025). Nanostructured Lipid Carrier-Based Nanoformulations for Atopic Dermatitis: A Comprehensive Review. Journal of Ravishankar University (Part-B: Science), 38(2), pp. 122-156. DOI:DOI: https://doi.org/10.52228/JRUB.2025-38-2-11

REFERENCES

1. Chauhan I, Yasir M, Verma M, Singh AP. Nanostructured Lipid Carriers: A Groundbreaking Approach for Transdermal Drug Delivery. Adv Pharm Bull. 2020 Feb 18;10(2):150–65.

2. Li B, Ge ZQ. Nanostructured Lipid Carriers Improve Skin Permeation and Chemical Stability of Idebenone. AAPS PharmSciTech. 2012 Mar 11;13(1):276–83.

3. Bieber T. Atopic Dermatitis. New England Journal of Medicine. 2008 Apr 3;358(14):1483–94.

4. Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022 Jan 20;21(1):21–40.

5. Elmowafy M, Al-Sanea MM. Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies. Saudi Pharmaceutical Journal. 2021 Sep;29(9):999–1012.

6. Stefanov SR, Andonova VY. Lipid Nanoparticulate Drug Delivery Systems: Recent Advances in the Treatment of Skin Disorders. Pharmaceuticals. 2021 Oct 26;14(11):1083.

7. Guttman-Yassky E, Krueger JG. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum? Curr Opin Immunol. 2017 Oct;48:68–73.

8. Irvine AD, McLean WHI, Leung DYM. Filaggrin Mutations Associated with Skin and Allergic Diseases. New England Journal of Medicine. 2011 Oct 6;365(14):1315–27.

9. Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012 May;22(5):850–9.

10. Nakatsuji T, Chen TH, Narala S, Chun KA, Two AM, Yun T, et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Sci Transl Med. 2017 Feb 22;9(378).

11. Williams HC. Atopic Dermatitis. New England Journal of Medicine. 2005 Jun 2;352(22):2314–24.

12. Laughter MR, Maymone MBC, Mashayekhi S, Arents BWM, Karimkhani C, Langan SM, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017*. British Journal of Dermatology. 2021 Feb 29;184(2):304–9.

13. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis. J Am Acad Dermatol. 2014 Jul;71(1):116–32.

14. Hussaarts KGAM, van Doorn L, Eechoute K, Damman J, Fu Q, van Doorn N, et al. Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib. Pharmaceutics. 2020 Aug 20;12(9):788.

15. Boguniewicz M, Leung DYM. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011 Jul 20;242(1):233–46.

16. Arif ST, Khan MA, Frøslev P, Zaman S uz, Panou DA, Nielsen HM, et al. Nanostructured lipid carriers as a strategy to enhance oral levosulpiride delivery: An in vitro and ex vivo assessment. Int J Pharm. 2025 Jan 25;669.

17. Khan I, Sabu M, Hussein N, Omer H, Houacine C, Khan W, et al. Trans-resveratrol-loaded nanostructured lipid carrier formulations for pulmonary drug delivery using medical nebulizers. J Pharm Sci. 2025 May 1;

18. Irvine AD, McLean WHI, Leung DYM. Filaggrin Mutations Associated with Skin and Allergic Diseases. New England Journal of Medicine. 2011 Oct 6;365(14):1315–27.

19. Skinner OP, Jurczyluk J, Baker PJ, Masters SL, Rios Wilks AG, Clearwater MS, et al. Lack of protein prenylation promotes NLRP3 inflammasome assembly in human monocytes. Journal of Allergy and Clinical Immunology. 2019 Jun;143(6):2315-2317.e3.

20. Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. Journal of Allergy and Clinical Immunology. 2014 Jun;133(6):1626–34.

21. Nakatsuji T, Chen TH, Narala S, Chun KA, Two AM, Yun T, et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Sci Transl Med. 2017 Feb 22;9(378).

22. Contents Vol. 10, 2002–03. Neuroimmunomodulation. 2002;10(6):383–4.

23. Niederquell A, Kuentz M. Introduction of a Theoretical Splashing Degree to Assess the Performance of Low-Viscosity Oils in Filling of Capsules. AAPS PharmSciTech. 2011 Mar 1;12(1):323–30.

24. Chauhan I, Yasir M, Verma M, Singh AP. Nanostructured Lipid Carriers: A Groundbreaking Approach for Transdermal Drug Delivery. Adv Pharm Bull. 2020 Feb 18;10(2):150–65.

25. Khan S, Sharma A, Jain V. An Overview of Nanostructured Lipid Carriers and its Application in Drug Delivery through Different Routes. Adv Pharm Bull. 2023 Jul 10;13(3):446–60.

26. Apostolou M, Assi S, Fatokun AA, Khan I. The Effects of Solid and Liquid Lipids on the Physicochemical Properties of Nanostructured Lipid Carriers. J Pharm Sci. 2021 Aug;110(8):2859–72.

27. Rasaq Kayode O, Afeez Babatunde O. Cabenuva®: Differentiated service delivery and the community Pharmacists’ roles in achieving UNAIDS 2030 target in Nigeria. Saudi Pharmaceutical Journal. 2021 Aug;29(8):815–9.

28. Garg J, Pathania K, Sah SP, Pawar S V. Nanostructured lipid carriers: a promising drug carrier for targeting brain tumours. Futur J Pharm Sci. 2022 Dec 8;8(1):25.

29. Czajkowska-Kośnik A, Szekalska M, Winnicka K. Nanostructured lipid carriers: A potential use for skin drug delivery systems. Vol. 71, Pharmacological Reports. Elsevier B.V.; 2019. p. 156–66.

30. Ajiboye AL, Nandi U, Galli M, Trivedi V. Olanzapine loaded nanostructured lipid carriers via high shear homogenization and ultrasonication. Sci Pharm. 2021 Jun 1;89(2).

31. Haider M, Abdin SM, Kamal L, Orive G. Nanostructured Lipid Carriers for Delivery of Chemotherapeutics: A Review. Pharmaceutics. 2020 Mar 23;12(3):288.

32. Duong VA, Nguyen TTL, Maeng HJ. Preparation of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Drug Delivery and the Effects of Preparation Parameters of Solvent Injection Method. Molecules. 2020 Oct 18;25(20):4781.

33. Syed Azhar SNA, Ashari SE, Zainuddin N, Hassan M. Nanostructured Lipid Carriers-Hydrogels System for Drug Delivery: Nanohybrid Technology Perspective. Molecules. 2022 Jan 4;27(1):289.

34. Chauhan I, Yasir M, Verma M, Singh AP. Nanostructured lipid carriers: A groundbreaking approach for transdermal drug delivery. Vol. 10, Advanced Pharmaceutical Bulletin. Tabriz University of Medical Sciences; 2020. p. 150–65.

35. Khot C, Kolekar K, Dabhole S, Mohite A, Nadaf S, Kumbhar PS, et al. Optimized albendazole-loaded nanostructured lipid carrier gel: a redefined approach for localized skin cancer treatment. RSC Pharmaceutics [Internet]. 2024;1(5):1042–54. Available from: https://xlink.rsc.org/?DOI=D4PM00207E

36. Eichenfield LF, Stripling S, Fung S, Cha A, O’Brien A, Schachner LA. Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting. Vol. 24, Pediatric Drugs. Adis; 2022. p. 293–305.

37. Balaji, Goudanavar P. Advancing topical drug delivery: NLC innovations in dermatological therepeutics. Nano Trends. 2025 Jun;10:100108.

38. Mall J, Naseem N, Haider MdF, Rahman MA, Khan S, Siddiqui SN. Nanostructured lipid carriers as a drug delivery system: A comprehensive review with therapeutic applications. Intelligent Pharmacy. 2024 Sep;

39. Gomaa E, Fathi HA, Eissa NG, Elsabahy M. Methods for preparation of nanostructured lipid carriers. Methods. 2022 Mar;199:3–8.

40. Duong VA, Nguyen TTL, Maeng HJ, Chi SC. Data on optimization and drug release kinetics of nanostructured lipid carriers containing ondansetron hydrochloride prepared by cold high-pressure homogenization method. Data Brief. 2019 Oct;26:104475.

41. Gomaa E, Fathi HA, Eissa NG, Elsabahy M. Methods for preparation of nanostructured lipid carriers. Methods. 2022 Mar 1;199:3–8.

42. Datt N, Poonuru RR, Yadav PK. Development and characterization of griseofulvin loaded nanostructured lipid carrier gel for treating dermatophytosis. Food Hydrocolloids for Health. 2022 Dec 1;2.

43. Trotta M, Debernardi F, Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsification–diffusion technique. Int J Pharm. 2003 May;257(1–2):153–60.

44. Palaria B, Tiwari V, Tiwari A, Aslam R, Kumar A, Sahoo BM, et al. Nanostructured Lipid Carriers: A Promising Carrier in Targeted Drug Delivery System. Current Nanomaterials. 2023 Apr;8(1):23–43.

45. Wairkar S, Patel D, Singh A. Nanostructured lipid carrier based dermal gel of cyclosporine for atopic dermatitis-in vitro and in vivo evaluation. J Drug Deliv Sci Technol. 2022 Jun 1;72.

46. Osanlou R, Emtyazjoo M, Banaei A, Hesarinejad MA, Ashrafi F. Preparation of solid lipid nanoparticles and nanostructured lipid carriers containing zeaxanthin and evaluation of physicochemical properties. Colloids Surf A Physicochem Eng Asp. 2022 May 20;641.

47. Teaima MH, Badawi NM, Attia DA, El-Nabarawi MA, Elmazar MM, Mousa SA. Efficacy of pomegranate extract loaded solid lipid nanoparticles transdermal emulgel against Ehrlich ascites carcinoma. Nanomedicine. 2022 Jan 1;39.

48. Ayesha BT, Erum A, Shahid N, Tulain UR, Saleem U. An effective approach in osteoarthritis: Diacerein-loaded solid lipid nanoparticles, preparation and evaluation for targeted therapy. J Drug Deliv Sci Technol. 2025 Jun 1;108.

49. Vogelaar A, Marcotte S, Cheng J, Oluoch B, Zaro J. Use of Microfluidics to Prepare Lipid-Based Nanocarriers. Pharmaceutics. 2023 Mar 24;15(4):1053.

50. Ahalwat S, Bhatt DC, Rohilla S. Quality by Design (QbD) based Formulation Optimization of Isoniazid Loaded Novel Nanostructured Lipid Carriers for Controlled Release Effect. J Pharm Innov. 2023 Dec 21;18(4):1685–700.

51. Sharma G, Thakur K, Raza K, Singh B, Katare OP. Nanostructured Lipid Carriers: A New Paradigm in Topical Delivery for Dermal and Transdermal Applications. Crit Rev Ther Drug Carrier Syst. 2017;34(4):355–86.

52. Rizwanullah Md, Ahmad MZ, Garg A, Ahmad J. Advancement in design of nanostructured lipid carriers for cancer targeting and theranostic application. Biochimica et Biophysica Acta (BBA) - General Subjects. 2021 Sep;1865(9):129936.

53. Bhavar A, Kolekar KA, Yadav T, Kole K, Bhagwat D, Singh SK, et al. Formulation of repurposed celecoxib-loaded nanostructured lipid carriers using Box-Behnken design, its characterization, and anticancer evaluation. Ann Pharm Fr. 2025;

54. Sharma S, Thukral R, Singla L Das, Singla N, Choudhury D. Quercetin-loaded solid lipid nanoparticles for enhanced anti-helminthic activity. Int J Pharm. 2025 Mar 15;672.

55. Pooja D, Tunki L, Kulhari H, Reddy BB, Sistla R. Optimization of solid lipid nanoparticles prepared by a single emulsification-solvent evaporation method. Data Brief. 2016 Mar;6:15–9.

56. Hemrajani C, Negi P, Parashar A, Gupta G, Jha NK, Singh SK, et al. Overcoming drug delivery barriers and challenges in topical therapy of atopic dermatitis: A nanotechnological perspective. Vol. 147, Biomedicine and Pharmacotherapy. Elsevier Masson s.r.l.; 2022.

57. Pooja D, Tunki L, Kulhari H, Reddy BB, Sistla R. Optimization of solid lipid nanoparticles prepared by a single emulsification-solvent evaporation method. Data Brief. 2016 Mar;6:15–9.

58. Ahalwat S, Bhatt DC, Rohilla S. Quality by Design (QbD) based Formulation Optimization of Isoniazid Loaded Novel Nanostructured Lipid Carriers for Controlled Release Effect. J Pharm Innov. 2023 Dec 21;18(4):1685–700.

59. Dash SK, Patra CN, Acharjya SK, Jena GK, Panigrahi KC, Kumar NK, et al. Development and Characterization of Paliperidone Loaded Nanostructured Lipid Carrier. Indian Journal of Pharmaceutical Education and Research. 2022 Oct 1;56(4):1003–12.

60. Vogelaar A, Marcotte S, Cheng J, Oluoch B, Zaro J. Use of Microfluidics to Prepare Lipid-Based Nanocarriers. Pharmaceutics. 2023 Mar 24;15(4):1053.

61. Umerska A, Mouzouvi CRA, Bigot A, Saulnier P. Formulation and nebulization of fluticasone propionate-loaded lipid nanocarriers. Int J Pharm. 2015 Aug 11;493(1–2):224–32.

62. Chavan SS, Ingle SG, Vavia PR. Preparation and characterization of solid lipid nanoparticle-based nasal spray of budesonide. Drug Deliv Transl Res. 2013 Oct;3(5):402–8.

63. Üner M. Characterization and Imaging of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers. In: Handbook of Nanoparticles. Cham: Springer International Publishing; 2016. p. 117–41.

64. Waghule T, Rapalli VK, Gorantla S, Saha RN, Dubey SK, Puri A, et al. Nanostructured Lipid Carriers as Potential Drug Delivery Systems for Skin Disorders. Curr Pharm Des. 2020 Oct 23;26(36):4569–79.

65. Shaheen ESGE, Anwar W, Abu-Elyazid SK, Afouna MI. DEVELOPMENT, SCREENING AND OPTIMIZATION OF ROSUVASTATIN LOADED NANOSTRUCTURED LIPID CARRIERS FOR IMPROVED THERAPEUTIC EFFICACY. Universal Journal of Pharmaceutical Research [Internet]. 2024 Nov 15; Available from: https://ujpronline.com/index.php/journal/article/view/1212

66. Kaur N, Gautam P, Nanda D, Meena AS, Shanavas A, Prasad R. Lipid Nanoparticles for Brain Tumor Theranostics: Challenges and Status. Bioconjug Chem. 2024 Sep 18;35(9):1283–99.

67. Sharma G, Thakur K, Raza K, Singh B, Katare OP. Nanostructured Lipid Carriers: A New Paradigm in Topical Delivery for Dermal and Transdermal Applications [Internet]. Vol. 34, Critical ReviewsTM in Therapeutic Drug Carrier Systems. 2017. Available from: www.begellhouse.com

68. Avinash M, Swami B, Nagoba SN. Formulation, Development And Characterization Of Nanostructured Lipid Carriers For Exemestane.

69. Rogers S, Gui L, Kovalenko A, Zoni V, Carpentier M, Ramji K, et al. Triglyceride lipolysis triggers liquid crystalline phases in lipid droplets and alters the LD proteome. Journal of Cell Biology. 2022 Nov 7;221(11).

70. Richard C, Cassel S, Blanzat M. Vesicular systems for dermal and transdermal drug delivery. RSC Adv. 2021;11(1):442–51.

71. Wissing SA, Müller RH. The influence of the crystallinity of lipid nanoparticles on their occlusive properties. Int J Pharm. 2002 Aug;242(1–2):377–9.

72. Anupam Kr S, Ankita G, Mona A. Journal of Drug Delivery and Therapeutics An International Peer Reviewed Journal Open access to Pharmaceutical and Medical research FORMULATION & CHARACTERIZATION OF NANOSTRUCTURED LIPID CARRIER (NLC) BASED GEL FOR TOPICAL DELIVERY OF ETORICOXIB. Journal of Drug Delivery & Therapeutics [Internet]. 2016;6(2):4–13. Available from: http://jddtonline.info

73. Fitriani EW, Avanti C, Rosana Y, Surini S. Nanostructured lipid carriers: A prospective dermal drug delivery system for natural active ingredients. Pharmacia. 2024;71:1–15.

74. Elmowafy M, Shalaby K, Ali HM, Alruwaili NK, Salama A, Ibrahim MF, et al. Impact of nanostructured lipid carriers on dapsone delivery to the skin: in vitro and in vivo studies. Int J Pharm. 2019 Dec;572:118781.

75. Hernández-Esquivel RA, Navarro-Tovar G, Zárate-Hernández E, Aguirre-Bañuelos P. Solid Lipid Nanoparticles (SLN). In: Nanocomposite Materials for Biomedical and Energy Storage Applications. IntechOpen; 2022.

76. Mall J, Naseem N, Haider MdF, Rahman MA, Khan S, Siddiqui SN. Nanostructured lipid carriers as a drug delivery system: A comprehensive review with therapeutic applications. Intelligent Pharmacy [Internet]. 2024 Sep; Available from: https://linkinghub.elsevier.com/retrieve/pii/S2949866X24001023

77. Alvarenga JM, Bieber T, Torres T. Emerging Biologic Therapies for the Treatment of Atopic Dermatitis. Drugs. Adis; 2024.

78. Kong X, Zhao Y, Quan P, Fang L. Development of a topical ointment of betamethasone dipropionate loaded nanostructured lipid carrier. Asian J Pharm Sci. 2016 Apr 1;11(2):248–54.

79. Toledo M da G, Lazo REL, Domingos EL, Zein AK El, Cobre A de F, Borba HHL, et al. Current status and evidence gap map of betamethasone-loaded nanostructured formulations as cutaneous delivery systems: A scoping review. J Drug Deliv Sci Technol. 2024 Nov;101:106275.

80. Cláudia Paiva-Santos A, Gama M, Peixoto D, Sousa-Oliveira I, Ferreira-Faria I, Zeinali M, et al. Nanocarrier-based dermopharmaceutical formulations for the topical management of atopic dermatitis. Vol. 618, International Journal of Pharmaceutics. Elsevier B.V.; 2022.

81. Madan JR, Khobaragade S, Dua K, Awasthi R. Formulation, optimization, and in vitro evaluation of nanostructured lipid carriers for topical delivery of Apremilast. Dermatol Ther. 2020 May 1;33(3).

82. Garg J, Pathania K, Sah SP, Pawar S V. Nanostructured lipid carriers: a promising drug carrier for targeting brain tumours. Futur J Pharm Sci. 2022 Dec;8(1).

83. Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Vol. 64, Advanced Drug Delivery Reviews. 2012. p. 83–101.

84. Essaghraoui A, Belfkira A, Hamdaoui B, Nunes C, Lima SAC, Reis S. Improved Dermal Delivery of Cyclosporine A Loaded in Solid Lipid Nanoparticles. Nanomaterials. 2019 Aug 27;9(9):1204.

85. Savić V, Ilić T, Nikolić I, Marković B, Čalija B, Cekić N, et al. Tacrolimus-loaded lecithin-based nanostructured lipid carrier and nanoemulsion with propylene glycol monocaprylate as a liquid lipid: Formulation characterization and assessment of dermal delivery compared to referent ointment. Int J Pharm. 2019 Oct;569:118624.

86. Saka OM, Aygüler Cİ, Özdemir NS, Sürücü B, Çakırlı E, Nemutlu E, et al. An Experimental Design Approach for Producing Curcumin-Loaded Solid Lipid Nanoparticles. Pharmaceuticals [Internet]. 2025 Mar 27;18(4):470. Available from: https://www.mdpi.com/1424-8247/18/4/470

87. Campos EVR, Proença PLF, Costa TG Da, De Lima R, Hedtrich S, Fraceto LF, et al. Hydrogels Containing Budesonide-Loaded Nanoparticles to Facilitate Percutaneous Absorption for Atopic Dermatitis Treatment Applications. ACS Appl Polym Mater. 2021 Sep 10;3(9):4436–49.

88. Ghate VM, Lewis SA, Prabhu P, Dubey A, Patel N. Nanostructured lipid carriers for the topical delivery of tretinoin. European Journal of Pharmaceutics and Biopharmaceutics. 2016 Nov 1;108:253–61.

89. Jitta SR, Kumar L. Nanostructured lipid carriers as an alternative carrier with high drug loading for targeting to brain tumors. In: Nanocarriers for Drug-Targeting Brain Tumors. Elsevier; 2022. p. 269–97.

90. Parashar P, Kanoujia J. Nanostructured lipid carriers: a novel platform for therapeutics. In: Advanced Nanoformulations: Theranostic Nanosystems: Volume 3. Elsevier; 2023. p. 303–32.

91. Chen-yu G, Chun-fen Y, Qi-lu L, Qi T, Yan-wei X, Wei-na L, et al. Development of a Quercetin-loaded nanostructured lipid carrier formulation for topical delivery. Int J Pharm. 2012 Jul;430(1–2):292–8.

92. Rapalli VK, Kaul V, Waghule T, Gorantla S, Sharma S, Roy A, et al. Curcumin loaded nanostructured lipid carriers for enhanced skin retained topical delivery: optimization, scale-up, in-vitro characterization and assessment of ex-vivo skin deposition. European Journal of Pharmaceutical Sciences. 2020 Sep;152:105438.

93. Salminen H, Weiss J. Solid lipid nanoparticles and nanostructured lipid carriers. In: Omega-3 Delivery Systems: Production, Physical Characterization and Oxidative Stability. Elsevier; 2021. p. 371–91.

94. Rajoriya V, Gupta R, Vengurlekar S, Surendra Singh U. Nanostructured lipid carriers (NLCs): A promising candidate for lung cancer targeting. Vol. 655, International Journal of Pharmaceutics. Elsevier B.V.; 2024.

95. Javed S, Mangla B, Almoshari Y, Sultan MH, Ahsan W. Nanostructured lipid carrier system: A compendium of their formulation development approaches, optimization strategies by quality by design, and recent applications in drug delivery. Vol. 11, Nanotechnology Reviews. De Gruyter Open Ltd; 2022. p. 1744–77.

96. Kong X, Zhao Y, Quan P, Fang L. Development of a topical ointment of betamethasone dipropionate loaded nanostructured lipid carrier. Asian J Pharm Sci. 2016 Apr;11(2):248–54.

97. Toledo M da G, Lazo REL, Domingos EL, Zein AK El, Cobre A de F, Borba HHL, et al. Current status and evidence gap map of betamethasone-loaded nanostructured formulations as cutaneous delivery systems: A scoping review. J Drug Deliv Sci Technol. 2024 Nov;101:106275.

98. Balaji, Goudanavar P. Advancing topical drug delivery: NLC innovations in dermatological therepeutics. Nano Trends. 2025 Jun;10:100108.

99. Pareek A, Kapoor DU, Yadav SK, Rashid S, Fareed M, Akhter MS, et al. Advancing lipid nanoparticles: A pioneering technology in cosmetic and dermatological treatments. Colloid Interface Sci Commun. 2025 Jan;64:100814.

100. GANNA S, KOTAKADI SM, MOHAMMED RA, SHAIK MI, NANNEPAGA JS. OPTIMIZATION AND CHARACTERIZATION OF RIVASTIGMINE-LOADED NANOSTRUCTURED LIPID CARRIERS. Int J Curr Pharm Res. 2021 May 15;46–51.

101. KARNATI V CHANDANA, N. VISHAL GUPTA, SANDEEP KANNA. NANOSTRUCTURED LIPID CARRIERS: THE FRONTIERS IN DRUG DELIVERY. Asian Journal of Pharmaceutical and Clinical Research. 2019 May 14;8–12.

102. Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Vol. 12, Nanomedicine: Nanotechnology, Biology, and Medicine. Elsevier Inc.; 2016. p. 143–61.

103. Fitriani EW, Avanti C, Rosana Y, Surini S. Nanostructured lipid carriers: A prospective dermal drug delivery system for natural active ingredients. Pharmacia. 2024 Mar 12;71:1–15.

104. Apostolou M, Assi S, Fatokun AA, Khan I. The Effects of Solid and Liquid Lipids on the Physicochemical Properties of Nanostructured Lipid Carriers. Vol. 110, Journal of Pharmaceutical Sciences. Elsevier B.V.; 2021. p. 2859–72.

105. Prathumwon C, Anuchapreeda S, Kiattisin K, Panyajai P, Wichayapreechar P, Surh YJ, et al. Curcumin and EGCG combined formulation in nanostructured lipid carriers for anti-aging applications. Int J Pharm X. 2025 Jun 1;9.

106. Fang CL, Al-Suwayeh SA, Fang JY. Send Orders of Reprints at bspsaif@emirates.net.ae Recent Patents Nanostructured Lipid Carriers (NLCs) for Drug Delivery and Targeting. Vol. 7, Nanotechnology. 2013.

107. Jameson M, Hirani A, Pathak Y V. Nanostructured lipid carriers. In: Nanotechnology in Nutraceuticals: Production to Consumption. CRC Press; 2016. p. 215–32.

108. Mahor AK, Singh PP, Gupta R, Bhardwaj P, Rathore P, Kishore A, et al. Nanostructured Lipid Carriers for Improved Delivery of Therapeutics via the Oral Route. J Nanotechnol. 2023 Nov 6;2023:1–35.

109. Unnisa A, Chettupalli AK, Alazragi RS, Alelwani W, Bannunah AM, Barnawi J, et al. Nanostructured Lipid Carriers to Enhance the Bioavailability and Solubility of Ranolazine: Statistical Optimization and Pharmacological Evaluations. Pharmaceuticals. 2023 Aug 14;16(8):1151.

110. Hashmi AR, Eltayib EM, Qaisar MN, Bafail DA, Salimi E, Arshad S, et al. Mucoadhesive aprepitant-loaded nanostructured lipid carriers containing sulfhydryl surfactant for enhanced oral drug bioavailability. J Drug Deliv Sci Technol. 2024 Sep 1;98.

111. Waghule T, Rapalli VK, Gorantla S, Saha RN, Dubey SK, Puri A, et al. Nanostructured Lipid Carriers as Potential Drug Delivery Systems for Skin Disorders. Curr Pharm Des. 2020 Oct 23;26(36):4569–79.

112. Vairo C, Collantes M, Quincoces G, Villullas S, Peñuelas I, Pastor M, et al. Preclinical safety of topically administered nanostructured lipid carriers (NLC) for wound healing application: biodistribution and toxicity studies. Int J Pharm. 2019 Oct;569:118484.

113. Gupta R, Xie H. Nanoparticles in Daily Life: Applications, Toxicity and Regulations. Journal of Environmental Pathology, Toxicology and Oncology. 2018;37(3):209–30.

114. Rodríguez-Gómez FD, Monferrer D, Penon O, Rivera-Gil P. Regulatory pathways and guidelines for nanotechnology-enabled health products: a comparative review of EU and US frameworks. Front Med (Lausanne). 2025 Mar 5;12.

115. Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, et al. Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics. 2018 May 18;10(2):57.

116. Patravale VB, Mandawgade SD. Novel cosmetic delivery systems: an application update. Int J Cosmet Sci. 2008 Feb 17;30(1):19–33.

117. Sawant K, Dodiya S. Recent Advances and Patents on Solid Lipid Nanoparticles. Recent Pat Drug Deliv Formul. 2008 Jun 1;2(2):120–35.

118. Mehta M, Bui TA, Yang X, Aksoy Y, Goldys EM, Deng W. Lipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development. ACS Materials Au. 2023 Nov 8;3(6):600–19.

119. Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, et al. Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic. Crit Rev Ther Drug Carrier Syst. 2009;26(6):523–80.

120. Thi TTH, Suys EJA, Lee JS, Nguyen DH, Park KD, Truong NP. Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines. Vaccines (Basel). 2021 Apr 8;9(4):359.

121. Herdiana Y, Wathoni N, Shamsuddin S, Muchtaridi M. Scale-up polymeric-based nanoparticles drug delivery systems: Development and challenges. OpenNano. 2022 Jul;7:100048.

122. Seo Y, Lim H, Park H, Yu J, An J, Yoo HY, et al. Recent Progress of Lipid Nanoparticles-Based Lipophilic Drug Delivery: Focus on Surface Modifications. Pharmaceutics. 2023 Feb 26;15(3):772.

123. Paliwal R, Babu RJ, Palakurthi S. Nanomedicine Scale-up Technologies: Feasibilities and Challenges. AAPS PharmSciTech. 2014 Dec 22;15(6):1527–34.

124. Onugwu AL, Nwagwu CS, Onugwu OS, Echezona AC, Agbo CP, Ihim SA, et al. Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases. Journal of Controlled Release. 2023 Feb;354:465–88.

125. Zhang Y, Wu BM. Current Advances in Stimuli-Responsive Hydrogels as Smart Drug Delivery Carriers. Gels. 2023 Oct 22;9(10):838.

126. Cheng Y, Lu Y. Physical stimuli-responsive polymeric patches for healthcare. Bioact Mater. 2025 Jan;43:342–75.

127. Pan Y, Liu Y, Yang S, Zhang C, Ullah Z. Recent research progress on the stimuli-responsive smart membrane: A review. Nanotechnol Rev. 2023 Jul 1;12(1).

128. Protsak IS, Morozov YM. Fundamentals and Advances in Stimuli-Responsive Hydrogels and Their Applications: A Review. Gels. 2025 Jan 2;11(1):30.

129. Rani A, Kaur R, Aldahish A, Vasudevan R, Balaji P, Dora CP, et al. Nanostructured Lipid Carriers (NLC)-Based Topical Formulation of Hesperidin for Effective Treatment of Psoriasis. Pharmaceutics. 2025 Apr 7;17(4):478.

130. Kukreja T, Saraf S. NLC BASED TOPICAL NANO FORMULATIONS FOR THE MANAGEMENT OF ATOPIC DERMATITIS: AN UPDATED REVIEW. Journal of Population Therapeutics and Clinical Pharmacology. 2022 Dec 28;

131. Filho D, Guerrero M, Pariguana M, Marican A, Durán-Lara EF. Hydrogel-Based Microneedle as a Drug Delivery System. Pharmaceutics. 2023 Oct 10;15(10):2444.

132. Elmowafy M, Al-Sanea MM. Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies. Vol. 29, Saudi Pharmaceutical Journal. Elsevier B.V.; 2021. p. 999–1012.

133. Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: A novel drug targeting carrier. Vol. 51, Journal of Drug Delivery Science and Technology. Editions de Sante; 2019. p. 255–67.

134. Akhtar N, Verma A, Pathak K. Exploring preclinical and clinical effectiveness of nanoformulations in the treatment of atopic dermatitis: Safety aspects and patent reviews. Bulletin of Faculty of Pharmacy, Cairo University. 2017 Jun;55(1):1–10.

135. Nguyen CN, Nguyen TTT, Nguyen HT, Tran TH. Nanostructured lipid carriers to enhance transdermal delivery and efficacy of diclofenac. Drug Deliv Transl Res. 2017 Oct 1;7(5):664–73.

136. Abdel-Mottaleb MMA. Nanoparticles for Treatment of Atopic Dermatitis. In: Nanoscience in Dermatology. Elsevier Inc.; 2016. p. 167–75.

137. Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Vol. 12, Nanomedicine: Nanotechnology, Biology, and Medicine. Elsevier Inc.; 2016. p. 143–61.

Related Images: